Health Care & Life Sciences » Pharmaceuticals | Boryung Pharmaceutical Co. Ltd.

Boryung Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
327,279
359,491
401,350
409,140
422,721
460,402
Cost of Goods Sold (COGS) incl. D&A
191,015
204,655
238,164
239,612
262,869
279,865
Gross Income
136,264
154,836
163,186
169,528
159,852
180,537
SG&A Expense
117,127
130,401
135,634
147,514
158,832
155,581
EBIT
19,137
24,435
27,552
22,014
1,020
24,956
Unusual Expense
-
-
270
390
2,248
3,478
Non Operating Income/Expense
2,740
4,663
842
2,406
76,478
1,571
Interest Expense
1,666
1,148
1,177
963
361
97
Pretax Income
20,314
28,615
27,817
21,536
76,380
29,126
Income Tax
6,187
7,024
7,516
15,849
19,902
7,229
Equity in Affiliates
-
-
-
73
-
-
Consolidated Net Income
14,127
21,591
20,301
5,614
56,478
21,897
Net Income
14,127
21,591
20,301
5,614
56,699
21,897
Net Income After Extraordinaries
14,127
21,591
20,301
5,614
56,699
21,897
Net Income Available to Common
14,127
21,591
20,301
5,614
56,699
21,897
EPS (Basic)
328.30
503.14
473.11
131.20
1,334.20
520.37
Basic Shares Outstanding
43
43
43
43
42
42
EPS (Diluted)
328.31
503.05
473.18
131.11
1,334.12
520.37
Diluted Shares Outstanding
43
43
43
43
42
42
EBITDA
29,690
35,561
40,333
37,334
17,277
41,098
Non-Operating Interest Income
103
12
26
164
1,356
165
Minority Interest Expense
-
-
-
-
220
-
Equity in Affiliates (Pretax)
-
-
-
-
178
946

About Boryung Pharmaceutical Co.

View Profile
Address
Boryung Building
Seoul SL 03127
Korea, Republic Of
Employees -
Website http://www.boryung.co.kr
Updated 07/08/2019
Boryung Pharmaceutical Co., Ltd. engages in the manufacture of of drug products. Its main products include Kanarb, Dukarb, Tuvero, TODULA, BESTO, and gelfosM. Its products include cardiovascular, antibiotics, anticancer, amino acid, cosmetics, gastrointestinal, and API.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.